Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

ClinicalTrials.gov ID: NCT03483103

Public ClinicalTrials.gov record NCT03483103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.

Study identification

NCT ID
NCT03483103
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
74 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 27, 2018 (Actual)
Primary completion
Sep 24, 2021 (Actual)
Completion
Dec 1, 2022 (Actual)
Last update posted
Dec 20, 2023

2018 – 2022

United States locations

U.S. sites
59
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
Banner MD Anderson Cancer Center Gilbert Arizona 85234 —
Local Institution - 0043 Gilbert Arizona 85234 —
Scripps Clinic La Jolla California 92037 —
UNC School of Medicine Los Angeles California 90095 —
University of California Los Angeles Los Angeles California 90095 —
Sutter Hematology and Oncology Sacramento California 95816 —
Sutter Medical Center Sacramento California 95816 —
Stanford Cancer Genetics Clinic Stanford California 94304 —
Local Institution - 0092 Stanford California 94305 —
Stanford Cancer Center Stanford California 94305 —
Local Institution - 0019 Atlanta Georgia 30342 —
The Blood and Marrow Transplant Group of Georgia Atlanta Georgia 30342 —
UNC School of Medicine Atlanta Georgia 30342 —
Local Institution - 0003 Chicago Illinois 60611 —
Northwestern University Feinberg School of Medicine Chicago Illinois 60611 —
Northwestern University Chicago Illinois 60611 —
Local Institution - 0016 Chicago Illinois 60637-1470 —
University of Chicago Chicago Illinois 60637-1470 —
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637 —
Local Institution - 0046 Lexington Kentucky 40536 —
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 —
University of Kentucky Lexington Kentucky 40536 —
Local Institution - 0064 Louisville Kentucky 40241 —
Norton Cancer Institute - Brownsboro Louisville Kentucky 40241 —
UNC School of Medicine Louisville Kentucky 40241 —
Johns Hopkins Oncology Center Bunting Blaustein Building Baltimore Maryland 21231 —
Local Institution - 0009 Baltimore Maryland 21231 —
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231 —
Local Institution - 0052 East Brunswick New Jersey 08816 —
Regional Cancer Care Associates East Brunswick New Jersey 08816 —
UNC School of Medicine East Brunswick New Jersey 08816 —
New York Oncology Hematology - Albany Cancer Center Albany New York 12208 —
New York Oncology Hematology P.C. Albany New York 12208 —
Local Institution - 0090 Rochester New York 14642 —
University of Rochester Cancer Center Rochester New York 14642 —
University of Rochester Medical Center Rochester New York 14642 —
Levine Cancer Institute Charlotte North Carolina 28204 —
Local Institution - 0021 Charlotte North Carolina 28204 —
Local Institution - 0039 Cincinnati Ohio 45236 —
Oncology Hematology Care, Inc. Cincinnati Ohio 45236 —
Oncology Hematology Care Cincinnati Ohio 45236 —
Local Institution - 0051 Portland Oregon 97213 —
Providence Cancer Center/Earle A. Chiles Res. Inst. Portland Oregon 97213 —
Providence Portland Medical Center Portland Oregon 97213 —
Local Institution - 0029 Pittsburgh Pennsylvania 15232 —
University of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh Pennsylvania 15232 —
Greenville Health System - Cancer Institute - Faris Road Greenville South Carolina 29605 —
Greenville Health System Greenville South Carolina 29615 —
Local Institution - 0037 Greenville South Carolina 29615 —
Local Institution - 0083 Dallas Texas 75390-7208 —
UNC School of Medicine Dallas Texas 75390 —
Intermountain Healthcare - LDS Hospital Blood and Marrow Transplant Salt Lake City Utah 84143 —
Intermountain Healthcare - LDS Hospital Salt Lake City Utah 84143 —
Local Institution - 0074 Salt Lake City Utah 84143 —
Northwest Medical Specialties Tacoma Washington 98405 —
UNC School of Medicine Tacoma Washington 98405 —
Local Institution - 0055 Milwaukee Wisconsin 53226 —
Medical College of Wisconsin, Froedtert Hospital Milwaukee Wisconsin 53226 —
UNC School of Medicine Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03483103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 20, 2023 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03483103 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →